Biological and Pharmaceutical Bulletin, 2017/08/01, Vol.40(8), pp.1247-1254
2017
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Mechanistic Study of Inhibitory Effects of Metformin and Atorvastatin in Combination on Prostate Cancer Cells in Vitro and in Vivo
- Ist Teil von
- Biological and Pharmaceutical Bulletin, 2017/08/01, Vol.40(8), pp.1247-1254
- Ort / Verlag
- Japan: The Pharmaceutical Society of Japan
- Erscheinungsjahr
- 2017
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- Metformin is a commonly used drug for the treatment of type II diabetes and atorvastatin is the most prescribed cholesterol-lowering statin. The present study investigated the effects and mechanisms of metformin and atorvastatin in combination on human prostate cancer cells cultured in vitro and grown as xenograft tumor in vivo. Metformin in combination with atorvastatin had stronger effects on growth inhibition and apoptosis in PC-3 cells than either drug alone. The combination also potently inhibited cell migration and the formation of tumorspheres. Metformin and atorvastatin in combination had a potent inhibitory effect on nuclear factor-kappaB (NF-κB) activity and caused strong decreases in the expression of its downstream anti-apoptotic gene Survivin. Moreover, strong decreases in the levels of phospho-Akt and phosphor-extracellular signal-regulated kinase (Erk)1/2 were found in the cells treated with the combination. The in vivo study showed that treatment of severe combined immunodeficient (SCID) mice with metformin or atorvastatin alone resulted in moderate inhibition of tumor growth while the combination strongly inhibited the growth of the tumors. Results of the present study indicate the combination of metformin and atorvastatin may be an effective strategy for inhibiting the growth of prostate cancer and should be evaluated clinically.
- Sprache
- Englisch; Japanisch
- Identifikatoren
- ISSN: 0918-6158eISSN: 1347-5215DOI: 10.1248/bpb.b17-00077Titel-ID: cdi_proquest_miscellaneous_1925896589
- Format
- –
- Schlagworte
- AKT protein, Animals, Antidiabetics, Antineoplastic Agents - pharmacology, Antineoplastic Agents - therapeutic use, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Apoptosis, Apoptosis - drug effects, Atorvastatin, Atorvastatin Calcium - pharmacology, Atorvastatin Calcium - therapeutic use, Cell adhesion & migration, Cell Line, Tumor, Cell migration, Cholesterol, combination, Diabetes mellitus, Extracellular signal-regulated kinase, Extracellular Signal-Regulated MAP Kinases - metabolism, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology, Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use, Hypoglycemic Agents - pharmacology, Hypoglycemic Agents - therapeutic use, Immunodeficiency, Inhibition, Inhibitor of Apoptosis Proteins - metabolism, Kinases, Male, Metformin, Metformin - pharmacology, Metformin - therapeutic use, Mice, SCID, Migration, NF-kappa B - metabolism, Prostate, Prostate cancer, Prostatic Neoplasms - drug therapy, Prostatic Neoplasms - pathology, Proto-Oncogene Proteins c-akt - metabolism, Rodents, Severe combined immunodeficiency, Survivin, Tumor Burden - drug effects, Tumors, Xenograft Model Antitumor Assays, Xenografts